01 / Research notes
Oral KPV questions
A peptide taken by mouth must survive the digestive process and reach the body in a useful way. The HHS policy makes human bioavailability documentation a condition for the exact oral formulation. Evidence for one formulation cannot simply be assigned to another capsule or liquid.
Even if absorption is documented, a separate clinical study would be needed to show that it improves a disease or symptom. Bioavailability is not proof of effectiveness.
02 / Research notes
Topical KPV questions
A topical preparation raises questions about local delivery, the condition being treated, skin integrity, ingredient stability, and potential irritation or contamination. Naming topical KPV in the policy does not establish that it treats eczema, wounds, or other skin conditions.
A persistent rash, wound, or changing lesion should be diagnosed before a treatment decision. Infection and other conditions may need established care.
03 / Research notes
How to compare the options
Ask which condition is being evaluated, whether the proposed route matches the policy, what quality testing applies, and which human evidence supports the exact product. FDA has identified major gaps in human safety information for KPV.
The choice is a clinical and pharmacy decision, not a preference that can be settled by an online ranking. No KPV product or prescription is guaranteed through an assessment.
Common questions
Is oral KPV allowed under the HHS policy?
The policy addresses qualifying oral KPV acetate with additional human bioavailability documentation for the specific formulation.
Is topical KPV proven to work for skin inflammation?
No adequate human evidence has established a benefit for a compounded topical KPV product.
Which route is safer?
There is not enough comparable human safety evidence to declare either route safer.
Sources and important information
Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. HHS's interim policy is conditional and may change. Treatment through Jonathan Larson MDPC requires clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational, not medical advice.